- Home
- BMRA vs BCAB Comparison
BMRA vs BCAB Comparison
Compare BMRA & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BMRA | BCAB |
|---|---|---|
| Founded | 1971 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 6.4M |
| IPO Year | 1995 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BMRA | BCAB |
|---|---|---|
| Price | $1.93 | $3.45 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 12.4K | ★ 36.8K |
| Earning Date | 04-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.86 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,311,000.00 | $300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.87 | $0.12 |
| 52 Week High | $4.60 | $6.52 |
Technical Indicators
Market Signals| Indicator | BMRA | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 32.27 | 44.19 |
| Support Level | N/A | $3.19 |
| Resistance Level | $2.23 | $5.18 |
| Average True Range (ATR) | 0.13 | 0.35 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 5.99 | 33.34 |
Price Performance
Historical ComparisonAbout BMRA Biomerica Inc.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.